See other companies on Welcome to the Jungle
Sense Biodetection
Molecular diagnostics
- 21-100 employees
- Healthcare
- B2B
- Biology
- Social Impact
- Science
- MedTech
- Abingdon, Oxford
Jump to section
Company mission
To transform healthcare worldwide by empowering patients and healthcare providers with innovative, point of care diagnostic products.
Our take
Sense Biodetection's platform ushers in a pioneering new class of molecular diagnostic testing. This brings the performance of central laboratory PCR testing into a rapid, easy-to-use, disposable format to detect a variety of deadly and costly diseases. Unconstrained by an instrument or reader, Sense Biodetection products can be use beyond traditional healthcare settings, enabling better access, outcomes, and value for patients and providers.
Sense Biodetection's vision to decentralise the healthcare system, through its flexible point-of-care testing capabilities for a variety of diseases, presents a foundational shift in an industry ripe for disruption. Sense are changing the way we manage healthcare and infectious diseases, and we expect even greater applications of their technology as they continue to grow.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Private Medical Insurance
- Life Assurance
- Share option scheme
Company values
- Collaboration - Our diverse team makes it happen through trust, inclusivity and respect. We are stronger together.
- Integrity - We make decisions for the right reasons and take pride in what we do
- Innovation - We dare to be brave, persevere and encourage creativity to push boundaries and deliver positive change
- Drive - We are passionate about our work, engaged and strive towards continuous improvement and growth individually and collectively
- Empowerment - We achieve results and inspire each other by having the confidence to use our voices and seize opportunities
- Accountability - We take ownership of our work and celebrate our successes whilst exceeding expectations
Funding (last 2 of 6 rounds)
Nov 2021
$15m
SERIES B
Apr 2021
$50m
SERIES B
Total funding: $85.1m
This company has top investors
Leadership
Harry Lamble
(Chief Business Development Officer)Previously Director of Business Development and Company Secretary at Oxford BioTherapeutics and at Imperial College’s Institute of Biomedical Engineering.